Compare iShares Core Growth Allocation ETF (AOR) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Biogen Inc — how do they compare? iShares Core Growth Allocation ETF trades at $70.11, while Biogen Inc trades at $208.19 (market cap $30.13B). Which is the better fit depends on your goals.
| AOR | BIIB | |
|---|---|---|
52-Week High | $70.12 | $216.63 |
52-Week Low | $62.26 | $128.93 |
Market Cap | — | $30.13B |
Sector | — | Health |
Enterprise Value | — | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, an iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% today. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF maintains a fixed 60/40 stock/bond allocation and rebalances semiannually with a low 0.20% fee. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
The ETF offers diversified exposure but faces risks from equity-bond correlation shifts and competition from pure equity funds. Analyst sentiment is mixed, balancing its simplicity against historical lagging returns. Key catalysts include fee waivers until December 2026 and semiannual rebalancing, but investors should weigh its conservative allocation against growth objectives.
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
